bioscienze ed economia l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Bioscienze ed economia PowerPoint Presentation
Download Presentation
Bioscienze ed economia

Loading in 2 Seconds...

play fullscreen
1 / 26

Bioscienze ed economia - PowerPoint PPT Presentation


  • 355 Views
  • Uploaded on

Convegno Science Generation Bioscienze ed economia Vittorio Chiesa Università degli studi di Milano-Bicocca FAST Milano, 14 marzo 2003 Index The healthcare context The role of biotech A worldwide overview on biotech industry The Italian situation Index The healthcare context

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Bioscienze ed economia' - libitha


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
bioscienze ed economia

Convegno Science Generation

Bioscienze ed economia

Vittorio Chiesa

Università degli studi di Milano-Bicocca

FAST

Milano, 14 marzo 2003

slide2

Index

  • The healthcare context
  • The role of biotech
  • A worldwide overview on biotech industry
  • The Italian situation
slide3

Index

  • The healthcare context
  • The role of biotech
  • A worldwide overview on biotech industry
  • The Italian situation
the healthcare context
The healthcare context
  • Increasing level of competition
  • Patent expiration
  • Industry performance indicators decline
slide5

Increasing level of competition

Inderall®1965

Tagamet®1977

Capoten® 1980

Seldane ®1985

AZT® 1987

Mevacor® 1987

Prozac® 1988

Dillucan® 1990

Recombinate® 1992

Invirase® 1995

Celebrex® 1999

Lopresor® 1975

Zantac®1983

Vasotec® 1985

Hismanial®1989

Videx® 1991

Pravachol® 1991

Zoloft® 1992

Sporanox® 1992

Kogenale® 1993

Norvi® 1996

Vioxx® 1999

patent expiration
Patent expiration
    • Generic products strongly penetrate
  • (50% of prescription drugs in US)
    • Revenues decrease by75% in three months since outpatenting
    • 40 bln $ of revenues will disappear in the next 5 years

Number of expiring patents

2001 53 2002 41 2003 58 2004 46

performance indicators decline
Performance indicators decline

Although R&D expenses grow continuously

1992 1997 2001

11 bln$ 18 bln$ 35 bln$

  • New drug approval decreases
  • Post-marketing product withdrawals grow
  • Sales growth declines

(9% in the ‘90ies vs. 5.3% foreseen in the first decade of the 2000)

the traditional paradigm is over
The traditional paradigm is over
  • Development of blockbusters (at least 1bln$ of revenues)
  • General-purpose products
  • Aggressive marketing
a new paradigm is required targeted treatments
A new paradigm is required:targeted treatments
  • Disease-centric approach to drug discovery
  • Cover of secondary care
  • Combination of products and services (self-diagnosis, patient training and education, disease management)
  • Targeted marketing
the new paradigm means stronger market pressure
The new paradigm means stronger market pressure
  • Earlier contacts with regulatory authorities
  • Continuous evaluation and stringent reviews
  • Shifting balance of power (to MCO)
  • Pricing fixed on the basis of medical results
the new paradigm is challenging
The new paradigm is challenging
  • Higher costs of development (clinical trials)
  • Lower selling volumes per drug
  • Lower price

but

  • Higher number of new and more effective drugs
slide12

Index

  • The healthcare context
  • The role of biotech
  • A worldwide overview on biotech industry
  • The Italian situation
the new paradigm means a new approach to r d

Drug

Development

Drug

Discovery

Production

&

Commercialization

The new paradigm meansa new approach to R&D

R&D

Approval

Understanding the disease at molecular level in drug discovery

Modeling and simulation in drug development

slide14

The new paradigm means a great opportunity for biotech companies

Drug

Development

Drug

Discovery

Production

&

Commercialization

Small Biotech

Big Biotech

Big Pharma Midsize Pharma

Approval

Enabling technology providers

slide15

Index

  • The healthcare context
  • The role of biotech
  • A worldwide overview on biotech industry
  • The Italian situation
slide16

The biotech industry in US and EU

Data 2001 in millions $

slide17

Biotech in Europe

Number of Companies

what is a cluster
What is a cluster
  • A cluster is “a geographical concentration of actors in vertical and horizontal relationships, showing a clear tendency of co-operating and of sharing their competences, all involved in a localized infrastructure of support”
  • In a cluster co-exist small biotech firms, R&D labs of large firms, universities and research centres, financial institutions, service companies, public support structures
advantages from clustering
Advantages from clustering
  • Sharing of knowledge, competencies and practices
  • Availability of skills
  • Collaboration
  • Support infrastructure
slide21

Growth mechanisms of a cluster

Generation of Start-ups and Spin-offs

Excellent Scientific Base

Establishment of large firm sites

Reinforcement of relations between Industry and Science

Growth of the scientific base

The trigger is facilitating the generation of new science-based companies

how clusters were born
How clusters were born
  • In US and UK, there were the conditions for the growth of a cluster:
    • excellent scientific base
    • strong enterpreneurial culture
    • propensity of finance to risky investments
  • In other countries (Germany, France, Scandinavian area) the public support helped create the conditions for the growth of a cluster
slide23

Index

  • The healthcare context
  • The role of biotech
  • A worldwide overview on biotech industry
  • The Italian situation
what is missing for a biotech cluster in lombardy
What is missing for a biotech cluster in Lombardy

Generation of Start-ups and Spin-offs

Biodevelopment

Companies

Scientific

Base

  • Mission
  • of a Biodevelopment Company
  • supporting researchers willing to
  • found a new company
  • supporting the management of the
  • project
  • attracting funds
  • hosting the companies in their
  • embryonic phase
  • International cases
  • BiomAG in Munich
  • Genopole in Evry (France)
  • Scientific and Technology Park in Heidelberg
  • Innovation Agencies and University Liaison Offices in Scandinavian countries
what we are doing
What we are doing
  • A EU funded project (Cleverbio) to study growth mechanisms and practices of biotech clusters and make a feasibility study for a biodevelopment company
  • A project funded by Fondazione Cariplo to build a network of bioincubators (University of Milano-Bicocca, Parco Tecnologico Padano, European Institute for Oncology - IFOM)